Onset Time: The Pharmacokinetic Metric Supplement Labels Don't Show

Onset Time: The Pharmacokinetic Metric Supplement Labels Don't Show

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

Onset time, technically Tmax, is the time from dosing to peak plasma concentration. For caffeine, that ranges from 39 minutes (cola) to 67 minutes (capsules), depending on the dosage form (Liguori et al., 1997). For L-theanine the figure is roughly 48 minutes after a capsule (Scheid et al., 2012); for oral melatonin the range is wide and highly individual (Harpsoe et al., 2015). Almost no supplement label states a Tmax. An oral dissolving strip (ODS) shortens onset by skipping gastric disintegration. MIHIYO Labs treats Tmax as a formulation target — not a marketing claim — and chooses film geometry to keep the active in oral contact long enough to matter.

What "onset time" actually means

In pharmacology, the number that captures how fast a dose begins to act is Tmax. It is the time, after a dose is taken, at which the active ingredient reaches its peak concentration in plasma. Tmax is one of the standard inputs to any bioequivalence assessment, along with Cmax (the peak concentration itself) and AUC (the total exposure). For prescription products, regulators require that generic and reference formulations stay within an 80 to 125 percent geometric-mean-ratio band on Cmax and AUC. Tmax is also reported.

Supplement labels almost never carry these numbers. A bottle will list 100 milligrams of caffeine or 1 milligram of melatonin and stop there. The implicit assumption is that the labeled dose tells you most of what you need to know. But milligrams do not predict when the ingredient starts to act, and onset time is often the practical answer the customer was looking for. A pre-workout that peaks in 30 minutes is a different product from one that peaks in 90 minutes, even at the same milligram dose.

This is the metric I want to make legible in this article.

Why Tmax varies so much across dosage forms

Three things drive Tmax for an oral dose: how long the dosage form takes to release the active, where in the digestive tract the active is absorbed, and how quickly the molecule crosses the relevant membrane. The dosage form sets the first two.

A compressed tablet has to disintegrate before any of the dose can dissolve and absorb. In-vivo imaging by Fredholt and colleagues measured real-world tablet disintegration in the stomach at roughly 10 to 26 minutes for immediate-release products.1 That is just the disintegration step — the dose has not yet reached the intestine, where most absorption happens.

A capsule does the same work, with the shell adding a short additional opening step before the contents are exposed to gastric fluid. A softgel adds shell swelling and rupture, and is sensitive to whether food is in the stomach.

An oral dissolving strip is a thin polymer film designed to hydrate and disintegrate in saliva within about 30 to 60 seconds, releasing the active directly against the oral mucosa.2 The release step is much shorter, and at least some of the dose is presented to a venous return that bypasses the portal vein and hepatic first-pass.3 For onset, that is the key engineering difference.

A liquid skips the disintegration step entirely. That is part of why coffee and cola peak faster than caffeine capsules in head-to-head pharmacokinetic comparisons.4

Dosage-form steps that decide Tmax — time to peak plasma concentration Tablets and capsules add a disintegration step (about 10 to 26 minutes for tablets in vivo) before any of the dose can absorb in the gut, while an oral dissolving strip disintegrates in saliva within 30 to 60 seconds and begins releasing at the oral mucosa. From swallowing to plasma peak: where the form decides the clock Each box is a delay step. Tmax is the sum. Tablet or capsule Oral dissolving strip Disintegration ~10-26 min (tablet) Gastric emptying Variable, food-sensitive Intestinal absorption Most uptake here Net Tmax — caffeine capsule, mean 67 ± 7 min (Liguori 1997) Film hydrates 30-60 s in saliva Mucosal contact Buccal absorption begins Swallowed fraction Adds gut + first-pass Mucosal onset starts within minutes; total Tmax depends on swallowed fraction Sources: Liguori, Hughes & Grass, 1997 (PMID 9329065); Fredholt et al., 2022 (PMID 36122785); Hoffmann et al., 2011 (PMID 21284577). Each step adds to Tmax — supplement labels do not report any of them.

What the studies show — three real onset numbers

Pulling specific Tmax values out of the literature makes the pattern concrete. Three ingredients with good human data:

Caffeine. Liguori, Hughes, and Grass dosed 13 healthy volunteers with 400 mg of caffeine from three sources — brewed coffee, cola, and capsules — in a crossover design. Mean Tmax was 42 ± 5 minutes for coffee, 39 ± 5 minutes for cola, and 67 ± 7 minutes for capsules; the capsule was significantly slower than the two beverages.4 Kamimori and colleagues separately compared caffeine in chewing gum against capsules and found a faster absorption rate from the gum format, because some of the dose is absorbed via the buccal mucosa during chewing.5 In a pooled pharmacokinetic analysis across many human studies, Grzegorzewski and colleagues confirmed that caffeine's oral bioavailability is nearly complete, so the dosage form mostly shifts onset, not total exposure.6

L-theanine. Scheid and colleagues administered 100 mg of L-theanine as a capsule or as a brewed green tea in healthy volunteers. The capsule gave a plasma Tmax of about 0.8 hours, which is roughly 48 minutes; green tea showed a comparable absorption profile.7 The point is the same: even for a small, water-soluble amino-acid analogue, peak plasma concentration is reached around three quarters of an hour after a capsule, not within minutes.

Melatonin. Harpsoe and colleagues' systematic review of melatonin pharmacokinetics reported large between-study variability in Tmax and Cmax for oral immediate-release melatonin, with bioavailability also highly variable.8 The clinical implication is that "1 mg of melatonin" can produce very different plasma curves in different formulations and different individuals.

Ingredient Format Reported Tmax Source
Caffeine Brewed coffee 42 ± 5 min Liguori et al., 1997
Caffeine Cola 39 ± 5 min Liguori et al., 1997
Caffeine Capsule 67 ± 7 min Liguori et al., 1997
Caffeine Chewing gum Faster than capsule (buccal route) Kamimori et al., 2002
L-theanine Capsule, 100 mg ~48 min (0.8 h) Scheid et al., 2012
L-theanine Green tea, 100 mg Comparable to capsule Scheid et al., 2012
Melatonin (oral, IR) Variable across studies Wide individual variability Harpsoe et al., 2015
Reported plasma Tmax across four supplement-ingredient formats Mean Tmax values from published human pharmacokinetic studies — caffeine cola, coffee, capsule, and L-theanine capsule — illustrate how dosage form, not just dose, decides time to peak plasma concentration. Mean reported Tmax — four ingredient-format pairings Lower bar = faster onset. Bars are reported means from peer-reviewed human studies. 0 15 30 45 60 75 Minutes to peak plasma concentration (Tmax) Caffeine — cola 39 ± 5 min (Liguori 1997) Caffeine — coffee 42 ± 5 min (Liguori 1997) L-theanine — capsule ~48 min (0.8 h) (Scheid 2012) Caffeine — capsule 67 ± 7 min (Liguori 1997) Melatonin — IR oral Wide between-study variability (Harpsoe 2015) Liquid / beverage Capsule (neutral) Capsule (caffeine, slowest) Wide variability across studies

These are not exotic numbers. They are basic pharmacology that the labeling does not surface.

Why supplement labels skip onset time

Three reasons, in honest order.

First, regulatory and structural. The FDA's dietary supplement framework requires identity, quantity, serving size, and qualifying nutrient information. It does not require pharmacokinetic disclosure. Adding a Tmax to a supplement label is not standard practice and can read as a drug-style claim.

Second, scientific. Most supplement formulations have never been tested in a Tmax study on the specific finished product. The literature numbers above are for caffeine, L-theanine, and melatonin as compounds in defined research preparations; they are not necessarily what any given brand's tablet, capsule, gummy, or strip would produce. Stating a Tmax that you have not measured is dishonest. Stating one that the literature only roughly bounds is misleading.

Third, marketing. "Works in 30 minutes" is a stronger marketing claim than "approaches peak plasma concentration approximately 40 to 60 minutes after a single dose, depending on individual variability and gastric state." The first is wrong; the second is right and sells less. Most brands resolve that tension by saying nothing.

I write about this openly because as a formulator I want the customer to be able to ask the right question. Faster onset is not always better — for sleep support, a long, gentle melatonin rise is closer to a physiologic profile than a fast, narrow peak. But onset is part of the product, and the customer should be able to reason about it.

What this means for MIHIYO formulations

For Energy-Focus, the onset target is straightforward. Caffeine is well absorbed by every oral route, so the ingredient question is settled. The form question is whether the strip format can get earlier mucosal contact than a capsule's typical 60- to 90-minute peak, and whether the user can actually feel the difference within the first 30 minutes. The Kamimori data on caffeine gum is the closest published proxy.5 I do not claim our strip reproduces those numbers without testing them — the next round of work I want done on this product is a small head-to-head onset study against a capsule.

For Sleep-Support, the calculation is different. Melatonin onset is wide and individual, and the EFSA-recognized claim is about reduced sleep onset latency, not about a fast plasma peak. The point of the strip format here is dose precision and a no-water bedtime ritual, not pushing onset earlier. I am explicit about this when customers ask.

Onset matters where it matters and not where it does not. The right discipline is to write the formulation to the use case, not to chase a Tmax just because it sounds appealing.

For readers who want one ingredient at a time, our piece on how fast caffeine strips actually work walks the buccal-mucosa case in detail, and the strip versus capsule comparison covers the route differences underneath the onset numbers.

What Tmax does not tell you

Onset is one number among several. The honest limits are worth stating.

A faster Tmax does not always mean a stronger or longer effect. The shape of the plasma curve after the peak matters at least as much. For caffeine, a higher early Cmax with the same AUC can mean a more intense onset and a sharper crash later; for melatonin, a fast peak can desynchronize from the physiologic nighttime release.

Tmax is also a single-dose concept. Daily-use supplements eventually reach a steady-state profile that the single-dose number does not capture. A user taking 50 mg of caffeine daily in any format will end up with a baseline tolerance that shifts the perceived onset more than a 20-minute Tmax difference would.

And Tmax is averaged across people. Individual variability is large — for melatonin, sometimes very large.8 A label-stated onset, even if it were allowed, would be a population average around a wide distribution.

The bottom line

The label tells you how much. The pharmacokinetic literature tells you when. For caffeine, L-theanine, and melatonin in immediate-release forms, peak plasma concentration generally lands somewhere between 30 minutes and an hour and a half after dosing, depending on the form. An oral dissolving strip is engineered to compress the early part of that window by skipping gastric disintegration and placing some of the dose on the oral mucosa, where buccal absorption can begin within minutes. For ingredients where onset is part of the use case, that is a real difference. For ingredients where it is not, the strip format earns its keep on other dimensions. Either way, knowing the Tmax helps the customer judge what they are actually buying.

References

  1. Fredholt F, Di Meo C, Sloth S, Müllertz A, Berthelsen R. Gastrointestinal in vivo disintegration profiles of immediate-release dosage forms. Eur J Pharm Biopharm. 2022;181:84-92. PMID: 36122785. DOI: 10.1016/j.ejpb.2022.09.012. <https://pubmed.ncbi.nlm.nih.gov/36122785/>
  2. Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv. 2011;8(3):299-316. PMID: 21284577. DOI: 10.1517/17425247.2011.553217. <https://pubmed.ncbi.nlm.nih.gov/21284577/>
  3. Bartlett JA, van der Voort Maarschalk K. Understanding the Oral Mucosal Absorption and Resulting Clinical Pharmacokinetics of Asenapine. AAPS PharmSciTech. 2012;13(4):1110-1115. PMID: 22936407. DOI: 10.1208/s12249-012-9839-7. <https://pubmed.ncbi.nlm.nih.gov/22936407/>
  4. Liguori A, Hughes JR, Grass JA. Absorption and subjective effects of caffeine from coffee, cola and capsules. Pharmacol Biochem Behav. 1997;58(3):721-726. PMID: 9329065. DOI: 10.1016/S0091-3057(97)00003-8. <https://pubmed.ncbi.nlm.nih.gov/9329065/>
  5. Kamimori GH, Karyekar CS, Otterstetter R, Cox DS, Balkin TJ, Belenky GL, Eddington ND. The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. Int J Pharm. 2002;234(1-2):159-167. PMID: 11839447. DOI: 10.1016/S0378-5173(01)00958-9. <https://pubmed.ncbi.nlm.nih.gov/11839447/>
  6. Grzegorzewski J, Bartsch F, Köller A, König M. Pharmacokinetics of caffeine: A systematic analysis of reported data for application in metabolic phenotyping and liver function testing. Front Pharmacol. 2022;12:752826. PMID: 35280254. DOI: 10.3389/fphar.2021.752826. <https://pubmed.ncbi.nlm.nih.gov/35280254/>
  7. Scheid L, Ellinger S, Alteheld B, Herholz H, Ellinger J, Henn T, Helfrich HP, Stehle P. Kinetics of L-theanine uptake and metabolism in healthy participants are comparable after ingestion of L-theanine via capsules and green tea. J Nutr. 2012;142(12):2091-2096. PMID: 23096008. DOI: 10.3945/jn.112.166371. <https://pubmed.ncbi.nlm.nih.gov/23096008/>
  8. Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71(8):901-909. PMID: 26008214. DOI: 10.1007/s00228-015-1873-4. <https://pubmed.ncbi.nlm.nih.gov/26008214/>

By — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.

0 comments

Leave a comment

Please note, comments need to be approved before they are published.